A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
A phase 2 trial of Trastuzumab rezetecan in cervical cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Overview
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT07051486 by Jiangsu HengRui Medicine Co., Ltd., with 60 participants planned, started 2025-10-11 and due to reach its primary completion in 2026-02. Interventions recorded: SHR-A1811 Injection. Conditions listed: Recurrent or Metastatic Cervical Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialPhase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialA Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialSHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Cervical cancer.
- TrialA Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialA Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialCamrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
- TrialA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.